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We are pleased that our publication [1] inspired the authors
to investigate the relationship of bovine leukemia virus
(BLV) and breast cancer in Chinese women. However,
aspects of the methodology presented cast doubt on
the accuracy of the results. The authors state (third
paragraph) “Similarly, the commercial ELISA kit used
in our study could readily detect BLV-specific anti-
bodies in all cows which were also positive for BLV by
PCR, but failed to detect reactive antibodies in Chinese
women with or without breast cancer.” Six commercial
BLV antibody testing kits are available for veterinary use
from the following companies: VMRD, IDEXX, Svanova,
Zoetis, Demeditec, and Biovet. Zhang et al. used a kit
from BioVet (personal communication with one of the
authors). The commercial kits were intended for cattle
and were standardized and extensively tested for the level
of anti-BLV antibody usually found in BLV-infected cattle,
which is much higher than that found in humans [2, 3].
Therefore, it would be unlikely that the veterinary kits
would detect the lower level of human anti-BLV antibody
that we were able to detect only with immunblotting, and
not by ELISA [3]. The commercial kits are not intended
for testing human sera; some would be negative for all
human sera because the final detection step involves a
labeled antibody to bovine, not human, immunoglobulin.
Kit directions explicitly say “for veterinary use only”
or “intended for detection of BLV antibodies in cattle
serum and milk.”
In addition, the PCR methodology is difficult to evaluate.
The second paragraph states “In this study, we conducted
seven PCRs according to Buehring’s group [3, 4] and one
published real-time PCR.” Our reported research [1, 4]
used in situ PCR, which requires sample preparation, cyc-
ling times/temperatures, reaction mix composition, and
a thermal cycler different from those used for standard
solution PCR and real-time PCR. It is impossible from
the information given to evaluate whether the authors’
in situ PCR techniques were equivalent to what we
used. Understandably, the authors were probably confined
by the journal’s word limit for a “Letter” and could not
give additional information.
It is plausible that the reported lack of detectable BLV
infection in Chinese women with breast cancer could
relate to lower consumption of bovine food products in
China compared to the USA. However, this conclusion
cannot be firmly made based on the methodology
presented in this publication; further research on this
topic is needed.
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